Satoshi Motoya

4.2k total citations
65 papers, 1.4k citations indexed

About

Satoshi Motoya is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Satoshi Motoya has authored 65 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Genetics, 43 papers in Epidemiology and 24 papers in Surgery. Recurrent topics in Satoshi Motoya's work include Inflammatory Bowel Disease (53 papers), Microscopic Colitis (38 papers) and Helicobacter pylori-related gastroenterology studies (11 papers). Satoshi Motoya is often cited by papers focused on Inflammatory Bowel Disease (53 papers), Microscopic Colitis (38 papers) and Helicobacter pylori-related gastroenterology studies (11 papers). Satoshi Motoya collaborates with scholars based in Japan, United States and Germany. Satoshi Motoya's co-authors include Toshifumi Hibi∥, Yasuo Suzuki, Mamoru Watanabe, Toshiyuki Matsui, Takayuki Matsumoto, Kenji Watanabe, Hiroaki Ito, Takanori Kanai∥, Haruhiko Ogata and Kohzoh Imai and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Satoshi Motoya

64 papers receiving 1.3k citations

Peers

Satoshi Motoya
Ian C. Lawrance Australia
Colleen McElree United States
Nathanael L. Dirks United States
Fabio Cataldi United States
Christopher Gasink United States
Thomas Griga Germany
P. Rutgeerts Belgium
Steven Y. Hua United States
Wendy Kampman United States
Filip J. Baert Belgium
Ian C. Lawrance Australia
Satoshi Motoya
Citations per year, relative to Satoshi Motoya Satoshi Motoya (= 1×) peers Ian C. Lawrance

Countries citing papers authored by Satoshi Motoya

Since Specialization
Citations

This map shows the geographic impact of Satoshi Motoya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Motoya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Motoya more than expected).

Fields of papers citing papers by Satoshi Motoya

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Motoya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Motoya. The network helps show where Satoshi Motoya may publish in the future.

Co-authorship network of co-authors of Satoshi Motoya

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Motoya. A scholar is included among the top collaborators of Satoshi Motoya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Motoya. Satoshi Motoya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peyrin‐Biroulet, Laurent, Jean‐Frédéric Colombel, Édouard Louis, et al.. (2024). Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies. SHILAP Revista de lepidopterología. 3(4). 539–550. 4 indexed citations
2.
Ando, Katsuyoshi, Mikihiro Fujiya, Nobuhiro Ueno, et al.. (2024). Effectiveness and Persistency of Ustekinumab Treatment for Ulcerative Colitis: A Phoenix retrospective Cohort Study. Crohn s & Colitis 360. 6(2).
3.
Matsuoka, Katsuyoshi, Tadakazu Hisamatsu, Yohei Mikami, et al.. (2023). Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study. Advances in Therapy. 40(6). 2902–2914. 1 indexed citations
4.
Hirayama, Daisuke, Satoshi Motoya, Toshifumi Ashida, et al.. (2023). Effectiveness and Factors Associated with Response to Golimumab in Japanese Patients with Ulcerative Colitis in Real Clinical Practice: The Phoenix Study. Inflammatory Intestinal Diseases. 8(3). 115–127. 4 indexed citations
5.
6.
Suzuki, Yasuo, Mamoru Watanabe, Toshiyuki Matsui, et al.. (2019). Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis. Inflammatory Intestinal Diseases. 4(4). 131–143. 7 indexed citations
7.
Motoya, Satoshi, Kenji Watanabe, Haruhiko Ogata, et al.. (2019). Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS ONE. 14(2). e0212989–e0212989. 72 indexed citations
8.
Fukushima, Kouhei, Akira Sugita, Kitaro Futami, et al.. (2018). Postoperative therapy with infliximab for Crohn’s disease: a 2-year prospective randomized multicenter study in Japan. Surgery Today. 48(6). 584–590. 22 indexed citations
9.
Tajiri, Hitoshi, Satoshi Motoya, Fukunori Kinjo, et al.. (2018). Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. PLoS ONE. 13(8). e0201956–e0201956. 4 indexed citations
10.
Suzuki, Yasuo, Satoshi Motoya, Hiroyuki Hanai, et al.. (2017). Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Journal of Gastroenterology. 52(9). 1031–1040. 8 indexed citations
11.
Muhammed, Rafeeq, Sue Protheroe, Ronald Bremner, et al.. (2016). P383. Short- and long-term outcomes of infliximab and calcineurin inhibitor treatment for steroid-refractory ulcerative colitis. Journal of Crohn s and Colitis. 10(suppl 1). S291.2–S292. 1 indexed citations
12.
13.
Fuyuno, Yuta, Keiko Yamazaki, Atsushi Takahashi, et al.. (2015). Genetic characteristics of inflammatory bowel disease in a Japanese population. Journal of Gastroenterology. 51(7). 672–681. 37 indexed citations
14.
Hibi∥, Toshifumi, Atsushi Sakuraba, Mamoru Watanabe, et al.. (2013). C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease. Journal of Gastroenterology. 49(2). 254–262. 50 indexed citations
15.
Suzuki, Yasuo, Satoshi Motoya, Hiroyuki Hanai, et al.. (2013). Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Journal of Gastroenterology. 49(2). 283–294. 133 indexed citations
16.
Hirano, Atsushi, Keiko Yamazaki, Junji Umeno, et al.. (2013). Association Study of 71 European Crohnʼs Disease Susceptibility Loci in a Japanese Population. Inflammatory Bowel Diseases. 19(3). 526–533. 49 indexed citations
17.
Imamura, Akira, et al.. (2011). Efficacy of the first infliximab administration influences long-term prognosis in refractory ulcerative colitis. Journal of Gastroenterology and Hepatology. 26. 111–112. 1 indexed citations
18.
Matsumoto, Takayuki, Mitsuo Iida, Satoshi Motoya, et al.. (2008). Therapeutic Efficacy of Infliximab on Patients with Short Duration of Crohn's Disease: A Japanese Multicenter Survey. Diseases of the Colon & Rectum. 51(6). 916–923. 14 indexed citations
19.
Hayashi, Toshiaki, Tohru Takahashi, Satoshi Motoya, et al.. (2001). MUC1 Mucin Core Protein Binds to the Domain 1 of ICAM-1. Digestion. 63(Suppl. 1). 87–92. 55 indexed citations
20.
Azuma, Naoki, Takao Endo, Yoshiaki Arimura, et al.. (2000). Prevalence of Barrett's esophagus and expression of mucin antigens detected by a panel of monoclonal antibodies in Barrett's esophagus and esophageal adenocarcinoma in Japan. Journal of Gastroenterology. 35(8). 583–592. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ian C. Lawrance Breakdown of academic impact, for papers by Colleen McElree Breakdown of academic impact, for papers by Nathanael L. Dirks Breakdown of academic impact, for papers by Fabio Cataldi Breakdown of academic impact, for papers by Christopher Gasink Breakdown of academic impact, for papers by Thomas Griga Breakdown of academic impact, for papers by P. Rutgeerts Breakdown of academic impact, for papers by Steven Y. Hua Breakdown of academic impact, for papers by Wendy Kampman Breakdown of academic impact, for papers by Filip J. Baert
Rankless by CCL
2026